Intermediate Macrophage Induction for Neonatal Lung Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP) are inadequate, with no effective prevention or treatment options that do not include negative side effects, and there is a need for novel compositions and methods to prevent or treat neonatal lung injury and BPD-associated pulmonary hypertension.
Innovation Solution
Administering a compound that promotes monocyte differentiation into antigen-presenting cell (APC)-specific intermediate macrophages, using compositions comprising compounds of Formula I, which modify macrophage polarization and induce phenotype switching to intermediate macrophages, administered via various routes including pulmonary, alveolar, and parenteral, combined with active agents to enhance immune response and reduce inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If steroids are administered as anti-inflammatory therapy, then inflammation is minimized, but the incidence of BPD is not decreased and mortality increases
Solution Approach 1:
The patent changes the parameter of macrophage polarization from traditional M1/M2 binary states to an intermediate macrophage state (iM2) characterized by specific phenotypic markers. This parameter change in immune cell differentiation resolves the contradiction by providing anti-inflammatory effects without the harmful side effects of steroids, as the intermediate macrophages maintain immune function while reducing pathological inflammation.
Solution Approach 2:
The patent introduces intermediate macrophages as an intermediary cell type between pro-inflammatory M1 and anti-inflammatory M2 macrophages. These intermediate macrophages act as mediators that provide the beneficial anti-inflammatory effects needed to treat BPD while avoiding the harmful effects of conventional steroid therapy, thus resolving the contradiction between reducing inflammation and maintaining safety.
2Reliability
If conventional treatments are used for BPD and ROP, then some symptoms are addressed, but no effective prevention or treatment options exist without negative side effects
Solution Approach 1:
The patent converts the harmful effect of excessive inflammation in BPD and ROP into a beneficial therapeutic approach by inducing intermediate macrophages that specifically reduce pathological inflammation while preserving protective immune functions. This resolves the contradiction by transforming the understanding of inflammation from something to be broadly suppressed (which causes side effects) to something that can be selectively modulated through intermediate macrophage induction.
Solution Approach 2:
The patent segments the macrophage population into distinct functional states (M1, intermediate, and M2) and specifically targets the induction of the intermediate state. This segmentation allows for precise control over the immune response, providing effective treatment for BPD and ROP without the broad immunosuppression and side effects associated with conventional steroid therapy.
3Object-affected harmful factors
If monocyte differentiation is directed toward traditional M2 macrophages, then anti-inflammatory effects are achieved, but immune function may be compromised
Solution Approach 1:
The patent changes the differentiation parameter from traditional M2 macrophage polarization to an intermediate macrophage state with distinct phenotypic characteristics. This parameter change resolves the contradiction by creating a cell type that provides anti-inflammatory effects through specific mechanisms (such as controlled cytokine production and tissue repair functions) while maintaining immune surveillance and response capabilities that would be compromised in full M2 polarization.
Data Source
AI summary
Provided herein are compositions and methods for method for inducing intermediate macrophages in a subject, the method comprising: administering to the subject a therapeutically effective amount of one or more compositions that comprise a compound of formula (I) or stereoisomer, enantiomer, tautomer or a pharmaceutically acceptable salt thereof:wherein the compound promotes monocyte differentiation into an antigen-presenting cell (APC)-specific intermediate macrophage lineage.